Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis (Q34478776)

2 August 2017

0 references

Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis (English)

1 reference

2 August 2017

1 reference

Yongfei Chen

1

1 reference

2 August 2017

Long Meng

series ordinal

2

1 reference

2 August 2017

Hua Shao

series ordinal

3

1 reference

2 August 2017

Feng Yu

series ordinal

4

1 reference

2 August 2017

15 November 2012

1 reference

2 August 2017

Hypertension Research

1 reference

2 August 2017

36

1 reference

2 August 2017

252-261

1 reference

2 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2012.185

2 August 2017

0 references

cites work

Selected major risk factors and global and regional burden of disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Angiotensin II and the endothelium: diverse signals and effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Effect of the new diagnostic criteria for ST-elevation and non-ST-elevation acute myocardial infarction on 4-year hospitalization: an analysis of hospital discharge records in the Veneto Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Changes in antihypertensive therapy--the role of adverse effects and compliance

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.185

7 January 2021

Identifiers

DOI

10.1038/HR.2012.185

1 reference

2 August 2017

1 reference